UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
photos

Hepatitis & HIV Clinical Trial Group (HCTG)

Viral hepatitis has emerged as a leading cause of morbidity and mortality in HIV infected individuals. The field of hepatitis C (HCV) treatment has been revolutionized by the emergence of more potent better tolerated treatments now available that can cure HCV infection in less time. The HCTG partners with industry collaborators to investigate therapeutic strategies for treatment and management of viral hepatitis and HIV infection. The HCTG conducts clinical trials evaluating cutting edge therapies in individuals infected with hepatitis C virus or hepatitis B virus, including individuals both with and without HIV coinfection. The HCTG also investigates new antiretroviral strategies to improve HIV management in treatment naïve and experienced individuals.

Areas of current focus:

  1. Use of HCV directly acting agents, including HCV protease inhibitors, polymerase inhibitors, and NS5A inhibitors, to shorten and improve HCV treatment in HIV-coinfection
  2. Interferon-free strategies to cure HCV infection (Genotypes 1-4) in patients with and without HIV coinfection
  3. Potent HIV antiretroviral therapy with long term tolerability

Recent publications in which HCTG participated:

  1. Luetkemeyer, A.F., et al., Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia. Journal of Acquired Immune Deficiency Syndromes, 2011. 58(3): p. e96-9.
  2. Dieterich, D., et al. Telaprevir in Combination with Pegylated Interferon-a-2a+RBV in HCV/HIV-co-infected Patients: A 24-Week Treatment Interim Analysis (Abstract 46) in 19th Conference on Retroviruses and Opportunistic Infections. 2012. Seattle, Washington.
  3. Sax, P.E., et al., Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet, 2012. 379(9835): p. 2439-48.

A list of current HCTG studies is available here.

For more information, please contact our outreach coordinator Jacque Clark at clarkj@php.ucsf.edu or (415) 476 4082 ext 352.